InsidersTradesSigma
Total declarations
Company
▲ Purchases (7 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
7
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-21.9%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by ADAMS ERIC A, Chairman & CEO. Insider active across 1 company, notably InMed Pharmaceuticals Inc.. Cumulatively, 7 disclosures have been recorded. Breakdown: 7 buys · 0 sell. Total volume traded: €93k. History available since 28 September 2021. The latest transaction was disclosed on 20 February 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations7 total
41,600 shares@ US$0.358714.9% of flowCommon StockSEC:0001213900-24-015703:0
Ideal exit: 16 Nov 2024 (T+270)
14,160 shares@ US$0.8940.18% mcap14.8% of flowCommon StockSEC:0001213900-22-020314:0
Ideal exit: 9 Jan 2023 (T+270)
8,560 shares@ US$0.850.10% mcap8.5% of flowCommon StockSEC:0001213900-22-019688:0
Ideal exit: 8 Jan 2023 (T+270)
8,800 shares@ US$1.7314.2% of flowCommon StockSEC:0001213900-21-050751
Ideal exit: 26 Jun 2022 (T+270)
8,800 shares@ US$1.730.20% mcap16.6% of flowCommon StockSEC:0001213900-21-050751:0
Ideal exit: 26 Jun 2022 (T+270)
11,400 shares@ US$1.75318.5% of flowCommon StockSEC:0001213900-21-050522
Ideal exit: 25 Jun 2022 (T+270)
11,400 shares@ US$1.7530.26% mcap21.7% of flowCommon StockSEC:0001213900-21-050522:0
Ideal exit: 25 Jun 2022 (T+270)
7 of 7 declarations
About ADAMS ERIC A
Eric A. Adams is the President & CEO of InMed Pharmaceuticals Inc. He oversees the company's operations and is responsible for the overall strategy. With a strong background in the pharmaceutical sector, Eric A. Adams is committed to advancing InMed Pharmaceuticals Inc.'s initiatives to develop innovative treatments.
